Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 and Olaparib in Advanced Solid Tumors
NCT02734004Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 7
01
Overview
A Phase 2 trial of durvalumab, olaparib in ovarian cancer, breast cancer, small cell lung cancer (SCLC), gastric cancer (GC), sponsored by AstraZeneca. Started Mar 2016; status: active, not recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
ovarian cancerbreast cancersmall cell lung cancer (SCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02734004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02734004.